-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, MYFr1ycrCafotYb1+orz/PuteIEwFJT6I1GX7z4Qrk1CiEL6cYxlnohwY+Yc/Tp3 3RQDTR+J3b6AFQP+bzWG6A== 0001169232-02-001825.txt : 20020930 0001169232-02-001825.hdr.sgml : 20020930 20020927173113 ACCESSION NUMBER: 0001169232-02-001825 CONFORMED SUBMISSION TYPE: SC 13D PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20020930 GROUP MEMBERS: JOSHUA D. SCHEIN, PH.D. GROUP MEMBERS: JUDSON A. COOPER FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: PRISM VENTURES LLC CENTRAL INDEX KEY: 0001193492 FILING VALUES: FORM TYPE: SC 13D MAIL ADDRESS: STREET 1: 420 LEXINGTON AVENUE STE 300 CITY: NEW YORK STATE: NY ZIP: 10170 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: HEMOXYMED INC CENTRAL INDEX KEY: 0000872947 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 391661164 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D SEC ACT: 1934 Act SEC FILE NUMBER: 005-55419 FILM NUMBER: 02775347 BUSINESS ADDRESS: STREET 1: 420 LEXINGTON AVENUE STREET 2: SUITE 300 CITY: NEW YORK STATE: NY ZIP: 10170 BUSINESS PHONE: 212-297-6221 MAIL ADDRESS: STREET 1: 420 LEXINGTON AVENUE STREET 2: SUITE 300 CITY: NEW YORK STATE: NY ZIP: 10170 FORMER COMPANY: FORMER CONFORMED NAME: OPHIDIAN PHARMACEUTICALS INC DATE OF NAME CHANGE: 19970714 SC 13D 1 d52054_13d.txt STATEMENTS SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ---------------- SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No: ______) HEMOXYMED, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0025 PER SHARE (Title of Class of Securities) 683725105 (CUSIP Number) Joshua D. Schein Prism Ventures LLC 420 Lexington Avenue, Suite 300 New York, New York 10170 (212) 297-6222 (Name, address and telephone number of person authorized to receive notices and communications) September 10, 2002 (Date of Event Which Requires Filing of This Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1 (b) (3) or (4), check the following box Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-1 (a) for other parties to whom copies are to be sent. (Continued on following pages) (Page 1 of 7 Pages) SCHEDULE 13D - -------------------------------------------------------------------------------- CUSIP NO. 683725105 Page 2 of 7 Pages - -------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Judson A. Cooper - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) |X| (b) - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS* PF - -------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) - -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION U.S. - -------------------------------------------------------------------------------- 7 SOLE VOTING POWER 4,534,534 ------------------------------------------------------------ NUMBER OF 8 SHARED VOTING POWER SHARES BENEFICIALLY 4,737,166 OWNED BY ------------------------------------------------------------ REPORTING 9 SOLE DISPOSITIVE POWER PERSON WITH 4,534,534 ------------------------------------------------------------ 10 SHARED DISPOSITIVE POWER 4,737,166 - -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 9,271,700 - -------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* - -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 19.1% - -------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON* IN - -------------------------------------------------------------------------------- 2 SCHEDULE 13D - -------------------------------------------------------------------------------- CUSIP NO. 683725105 Page 3 of 7 Pages - -------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Joshua D. Schein, Ph.D. - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) |X| (b) - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS* PF - -------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) - -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION U.S. - -------------------------------------------------------------------------------- 7 SOLE VOTING POWER 4,540,746 ------------------------------------------------------------ NUMBER OF 8 SHARED VOTING POWER SHARES BENEFICIALLY 4,737,166 OWNED BY ------------------------------------------------------------ REPORTING 9 SOLE DISPOSITIVE POWER PERSON WITH 4,540,746 ------------------------------------------------------------ 10 SHARED DISPOSITIVE POWER 4,737,166 - -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 9,277,912 - -------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* - -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 19.1% - -------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON* IN - -------------------------------------------------------------------------------- 3 SCHEDULE 13D - -------------------------------------------------------------------------------- CUSIP NO. 683725105 Page 4 of 7 Pages - -------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Prism Ventures LLC - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) |X| (b) - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS* WC - -------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) - -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware - -------------------------------------------------------------------------------- 7 SOLE VOTING POWER 0 ------------------------------------------------------------ NUMBER OF 8 SHARED VOTING POWER SHARES BENEFICIALLY 4,737,166 OWNED BY ------------------------------------------------------------ REPORTING 9 SOLE DISPOSITIVE POWER PERSON WITH 0 ------------------------------------------------------------ 10 SHARED DISPOSITIVE POWER 4,737,166 - -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 4,737,166 - -------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* - -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 9.8% - -------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON* OO - -------------------------------------------------------------------------------- 4 Page 5 of 7 Pages Schedule 13D Item 1. Security and Issuer. This Statement relates to the Common Stock, par value $0.0025 per share (the "Common Stock"), of Hemoxymed, Inc., a corporation organized and existing under the laws of the State of Delaware (the "Company"). The address of the principal executive office of the Company is 50 Lakeview Parkway, Suite III, Vernon Hills, Illinois 60061. Item 2. Identity and Background. (a, b, c and f) This Statement is being filed by (i) Judson A. Cooper , a U.S. citizen ("Cooper"), (ii) Joshua D. Schein, Ph.D. ("Schein"), a U.S. citizen and (iii) Prism Ventures LLC, a Delaware limited liability company ("Prism"). The principal business of Prism is to hold certain investments. Each of Schein and Cooper own 50% of Prism. The principal office of Prism is 420 Lexington Avenue, Suite 300, New York, New York 10170. Cooper, Schein and Prism are referred to herein collectively as the "Reporting Persons." (d and e) During the last five years, none of the Reporting Persons has been (i) convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors); or (ii) was a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities law or finding any violation with respect to such laws. Item 3. Source and Amount of Funds or Other Consideration. Prior to August 21, 2001, Prism, Cooper and Schein owned 14,464,627, 173,163 and 173,163 shares of common stock of Hemoxymed, Inc., a private company. On August 21, 2001, Hemoxymed, Inc. merged into the Company (formerly known as Ophidian Pharmaceuticals, Inc.). Prism, Cooper and Schein received 14,464,627, 173,163 and 173,163 shares of Common Stock of the Company in the merger, respectively. In November 2001, in connection with a private placement, the Company converted $242,065 of debt owed to Prism into 484,130 shares at $.50 per share. On April 10, 2002, Prism transferred 2,772,979 shares to a third party. On September 2, 2002, Prism transferred 4,361,371 shares of Common Stock to each of Cooper and Schein. On September 10, 2002, the Company merged with Molecular Geriatrics Corporation. In connection with the merger, Prism was issued 800,000 warrants to purchase Common Stock of the Company which are immediately exercisable at $.20 per share until September 10, 2012. Item 4. Purpose of Transactions Each of the Reporting Persons currently intend to hold the shares of Common Stock of the Company for investment purposes. None of the Reporting Persons has any current intention to purchase additional shares of Common Stock. Other than as discussed herein, none of the Reporting Persons has any plans or proposals which relate to or would result in (i) the acquisition of additional securities of the Company or the disposition of securities of the Company; (ii) an extraordinary corporate transaction, such as a merger, reorganization or liquidation involving the Company or any of its subsidiaries; (iii) a sale or transfer of a material amount of assets of the Company or of any of its subsidiaries; (iv) any change in the present board of directors or management of the Company, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board; (v) any material change in the present capitalization or dividend policy of the Company; (vi) any other material change in the Company's business or corporate structure; (vii) changes in the Company's charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Company by any person; (viii) causing a class of the Company's securities to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; (ix) a class of the Company's equity securities becoming eligible for termination of 5 Page 6 of 7 Pages registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934; or (x) any action similar to any of those enumerated above. Item 5. Interest in Securities of the Issuer. (a) Cooper may be deemed to be the beneficial owner of 9,271,700 shares of Common Stock, representing 19.1% of the outstanding shares of Common Stock. Such shares include 4,534,534 shares of Common Stock owned by Cooper and 4,737,166 shares of Common Stock owned by Prism. Schein may be deemed to be the beneficial owner of 9,277,912 shares of Common Stock, representing 19.1% of the outstanding shares of Common Stock. Such shares include 4,540,746 shares of Common Stock owned by Schein and 4,737,166 shares of Common Stock owned by Prism. Prism may be deemed to be the beneficial owner of 4,737,166 shares of Common Stock representing 9.8% of the outstanding shares of Common Stock. (b) Cooper may be deemed to have sole voting and dispositive power over 4,534,534 shares of Common Stock and share voting and dispositive power with Prism with respect to 4,737,166 shares of Common Stock. Schein may be deemed to have sole voting and dispositive power over 4,540,746 shares of Common Stock and share voting and dispositive power with Prism with respect to 4,737,166 shares of Common Stock. Prism may be deemed to share voting and dispositive power over 4,737,166 shares of Common Stock with Cooper and Schein. (c) None in addition to the transactions described in Item 3. (d-e) Not applicable. Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer. None Item 7. Material to be Filed as Exhibits. 1. Joint Filing Agreement between Judson A. Cooper, Joshua D. Schein, Ph.D. and Prism Ventures LLC. 6 Page 7 of 7 Pages Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated as of September 23, 2002 /s/ Judson A. Cooper ---------------------------- Judson A. Cooper Dated as of September 23, 2002 /s/ Joshua D. Schein ---------------------------- Joshua D. Schein, Ph.D. Prism Ventures LLC Dated as of September 23, 2002 By: /s/ Joshua D. Schein ------------------------- Name: Joshua D. Schein Title: Member 7 EX-1 3 d52054_ex1.txt JOINT FILING AGREEMENT EXHIBIT 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(f) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of the Schedule 13D to which this Agreement is an exhibit (and any further amendment filed by them) with respect to the shares of Common Stock, $.0025 par value, of Hemoxymed, Inc. This agreement may be executed simultaneously in any number of counterparts, all of which together shall constitute one and the same instrument. Dated: September 23, 2002 /s/ Judson A. Cooper ------------------------------ Judson A. Cooper /s/ Joshua D. Schein ------------------------------ Joshua D. Schein, Ph.D. Prism Ventures LLC By:/s/ Joshua D. Schein --------------------------- Name: Joshua D. Schein Title: Member -----END PRIVACY-ENHANCED MESSAGE-----